Ethical Research - Sun Pharma launches Drizalma Sprinkle in US market

Sun Pharmaceutical Industries Ltd. announced that one of its wholly-owned subsidiaries has launched Drizalma Sprinkle (duloxetine delayed-release capsules) in the U.S. for oral use. Drizalma Sprinkle is a serotonin and norepinephrine reuptake inhibitor (SNRI) designed for the treatment of various neuro-psychiatric and pain disorders in patients who have difficulty swallowing – a problem that is estimated to affect approximately 30-35% of long-term care residents. The U.S. Food and Drug Administration (FDA) approved Drizalma Sprinkle on July 19, 2019.

The availability of Drizalma Sprinkle expands Sun Pharma’s portfolio of alternative formulation products designed for individuals with swallowing difficulties, the risk of which increases with age and exposure to age-related diseases and conditions - including depression, anxiety, and pain disorders.1-2 Drizalma Sprinkle joins Ezallor Sprinkle (Rosuvastatin) and Kapspargo Sprinkle™ (metoprolol succinate) extended-release capsules as the third product in Sun Pharma’s US portfolio designed for individuals in long-term care. It is common practice in long-term care facilities to crush medications to ease administration, but crushing tablets introduces additional risks to the administration process.

Quick Trial – 9407533858/0731-4704705

or mail us here - support@ethicalresearch.co.in

or visit - http://ethicalresearch.co.in/home/freetrial